7827 Hankang-KY Chuang: Subsidiary FBD Biologics Announces Strategic Collaboration with INVO Bioscience (Shanghai) for Refractory Solid Tumor Therapy

Date of Announcement: July 9, 115 Date of Statement: July 8, 115 Time of Statement: 16:29 Company Code: 7827 Company Name: Hankang-KY Chuang Subject: Announcement on behalf of subsidiary FBD Biologics Limited regarding the signing of a Strategic Memorandum of Understanding (MOU) with INVO Bioscience (Shanghai) Co., Ltd. Applicable Clause: Clause 10 Factual Date: July 8, 115

Details: 1. Factual Date: 7/8/115 2. Counterparty to the Agreement or Commitment: INVO Bioscience (Shanghai) Co., Ltd. 3. Relationship with the Company: None 4. Effective and Expiry Dates (or Termination Date) of the Agreement or Commitment: None 5. Main Content (Not applicable if terminated): FBD Biologics Limited, a subsidiary of the Company, has signed a Strategic Memorandum of Understanding (MOU) with INVO Bioscience (Shanghai) Co., Ltd.

Under the MOU, both parties will leverage their respective clinical-stage products and technology platforms to conduct preclinical and translational research aimed at exploring combination therapy strategies for refractory solid tumors.

This collaboration will investigate the combined application of HCB101, a clinical-stage fusion protein, with INVO’s FAK inhibitor IN10018/ifebemtinib and FAP-targeted antibody-drug conjugate (ADC) OMTX705.

6. Restrictive Clauses (Not applicable if terminated): None 7. Commitments (Not applicable if terminated): None 8. Other Important Agreements (Not applicable if terminated): None 9. Impact on the Company's Financials and Operations: This MOU serves to confirm mutual cooperation intent and currently has no material impact on the Company’s financials or operations.

Both parties will evaluate potential next steps based on the outcomes of preclinical and translational research. 10. Specific Purpose: To support the future development strategy of the Company’s core products and long-term growth. 11. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly listed company or above, this material information also qualifies as an event under Article 7, Paragraph 8 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders’ rights or securities prices):

(1) This MOU is intended for preclinical and translational research exploration. Any subsequent collaboration or development arrangements will be determined based on research outcomes and further mutual agreements, and will be announced and reported in accordance with relevant regulations.

(2) Investors should be aware that there are risks associated with uncertainty in future research results, final agreement terms, and progress of the collaboration.